Clinical trial
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark)…
NCT00117845 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00117845 |
|---|---|
| Title | Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia |
| Official title | Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Adult T-Cell |
| Intervention type | Biological |
| Interventions | Denileukin diftitox (Ontak) |
| Enrollment | 17 |
| Start date | Jul 11, 2005 |
| Primary completion | Dec 31, 2011 |
| Completion | Jun 30, 2013 |
| First posted | Jul 8, 2005 |
| Last update posted | Nov 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: